APPLY TODAY!
https://zintellect.com/Opportunity/Details/NIH-NIAID-TTIPO-TTFP-2021
Ready to be a critical part of the NIAID team with advancing the development and commercialization of NIAID and CDC inventions?
The National Institute of Allergy and Infectious Diseases (NIAID) Technology Transfer and Intellectual Property Office (TTIPO) is seeking motivated applicants with a strong scientific background and excellent communication skills for the NIAID Technology Transfer Fellowship Program (TTFP).
Why should I apply? Take advantage of this opportunity to learn about the policies and laws that drive technology transfer at NIH and develop skills for a career in technology transfer. The TTFP will prepare Fellows for technology transfer positions within universities, industry, or the government (with most former Fellows becoming federal employees).
What will I be doing? Fellows in the NIAID TTFP will be mentored on how NIAID:
· Reviews inventions reported by NIAID or CDC scientists for potential patenting, licensing, and/or marketing.
· Negotiates confidential disclosure agreements, material transfer agreements, clinical trial agreements, cooperative research and development agreements, and other technology transfer agreements for NIAID.
· Negotiates licenses for NIAID and CDC technologies and monitors licenses for compliance.
· Manages a portfolio of patent applications, issued patents and other forms of intellectual property.
· Promotes collaborations with academia, industry, nonprofits, and government agencies.
Where will I be located? Rockville, MD
Appointments may result in a virtual placement due to COVID-19 impacts.
What are the benefits? Fellows in the NIAID TTFP receive the following benefits:
· A one year appointment that may be renewed up to three years
o 1st year stipend rate: $58,980 annually
o 2nd year stipend rate: $64,800 annually
o 3rd year stipend rate: $72,000 annually
· Health Insurance Supplement
· A training and travel allowance of $5,000 is established for each participant annually.
No comments:
Post a Comment